NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors

被引:3
作者
Wang, Yahui [1 ,2 ]
Liu, Xinyi [1 ]
Zuo, Xianbo [3 ]
Wang, Cuiling [1 ]
Zhang, Zheng [1 ]
Zhang, Haitao [1 ]
Zeng, Tao [4 ]
Chen, Shunqi [1 ]
Liu, Mengyu [1 ]
Chen, Hongxia [1 ]
Song, Qingfeng [5 ]
Li, Qi [1 ,6 ]
Yang, Chenning [1 ]
Le, Yi [7 ]
Xing, Jinliang [8 ]
Zhang, Hongxin [2 ,9 ]
An, Jiaze [10 ]
Jia, Weihua [11 ,12 ]
Kang, Longli [13 ]
Zhang, Hongxing [6 ]
Xie, Hui [14 ]
Ye, Jiazhou [15 ]
Wu, Tianzhun [15 ]
He, Fuchu [2 ]
Zhang, Xuejun [16 ,17 ]
Li, Yuanfeng [1 ]
Zhou, Gangqiao [1 ,18 ]
机构
[1] Beijing Inst Radiat Med, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[2] Beijing Inst Lifeom, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Dermatol, Dept Pharm, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Fac Hepatobiliary Pancreat Surg, Med Ctr 1, Beijing, Peoples R China
[5] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China
[6] Univ South China, Sch Med, Dept Neurosci, Hengyang, Hunan, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 5, Beijing, Peoples R China
[8] Air Force Med Univ, Expt Teaching Ctr Basic Med, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China
[9] Air Force Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China
[10] Air Force Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
[11] State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China
[12] Sun Yat Sen Univ, Dept Expt Res, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[13] Xizang Minzu Univ, Sch Med, Key Lab Mol Genet Mech & Intervent Res High Altitu, Key Lab High Altitude Environm & Genes Related Dis, Xianyang, Shaanxi, Peoples R China
[14] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Oncol, Med Ctr 5, Beijing, Peoples R China
[15] Guangxi Med Univ, Guangxi Liver Canc Diag & Treatment Engn & Technol, Dept Hepatobiliary & Pancreat Surg, Canc Hosp, Nanning, Guangxi, Peoples R China
[16] Anhui Med Univ, Affiliated Hosp 1, Dept Dermatol, Hefei, Anhui, Peoples R China
[17] Anhui Med Univ, Affiliated Hosp 1, Inst Dermatol, Hefei, Anhui, Peoples R China
[18] Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源
CELL GENOMICS | 2024年 / 4卷 / 05期
基金
中国国家自然科学基金;
关键词
GENOME-WIDE ASSOCIATION; DNA-REPAIR; SUSCEPTIBILITY LOCUS; READ ALIGNMENT; CANCER; EXPRESSION; NBS1; PATHOGENICITY; POLYMORPHISM; FRAMEWORK;
D O I
10.1016/j.xgen.2024.100550
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To identify novel susceptibility genes for hepatocellular carcinoma (HCC), we performed a rare -variant association study in Chinese populations consisting of 2,750 cases and 4,153 controls. We identified four HCCassociated genes, including NRDE2 , RANBP17 , RTEL1 , and STEAP3 . Using NRDE2 (index rs199890497 [p.N377I], p = 1.19 3 10 - 9 ) as an exemplary candidate, we demonstrated that it promotes homologous recombination (HR) repair and suppresses HCC. Mechanistically, NRDE2 binds to the subunits of casein kinase 2 (CK2) and facilitates the assembly and activity of the CK2 holoenzyme. This NRDE2-mediated enhancement of CK2 activity increases the phosphorylation of MDC1 and then facilitates the HR repair. These functions are eliminated almost completely by the NRDE2-p.N377I variant, which sensitizes the HCC cells to poly(ADP-ribose) polymerase (PARP) inhibitors, especially when combined with chemotherapy. Collectively, our findings highlight the relevance of the rare variants to genetic susceptibility to HCC, which would be helpful for the precise treatment of this malignancy.
引用
收藏
页数:34
相关论文
共 35 条
[21]   Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors [J].
Yuna Suzuki ;
Wu Wenwen ;
Tomohiko Ohta ;
Shin-ichi Hayashi .
Breast Cancer, 2022, 29 :77-91
[22]   RETRACTED: RAD54L promotes progression of hepatocellular carcinoma via the homologous recombination repair pathway [J].
Li, Hongda ;
Zhuang, Haiwen ;
Gu, Tengfei ;
Li, Guangyu ;
Jiang, Yuhang ;
Xu, Sanrong ;
Zhou, Qing .
FUNCTIONAL & INTEGRATIVE GENOMICS, 2023, 23 (02)
[23]   Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency [J].
Simoneau, Antoine ;
Pratt, Charlotte B. ;
Wu, Hsin-Jung ;
Rajeswaran, Shreya S. ;
Comer, Charlotte Grace ;
Sudsakorn, Sirimas ;
Zhang, Wenhai ;
Liu, Shangtao ;
Meier, Samuel R. ;
Choi, Ashley H. ;
Khendu, Tenzing ;
Stowe, Hannah ;
Shen, Binzhang ;
Whittington, Douglas A. ;
Chen, Yingnan ;
Yu, Yi ;
Mallender, William D. ;
Feng, Tianshu ;
Andersen, Jannik N. ;
Maxwell, John P. ;
Throner, Scott .
MOLECULAR CANCER THERAPEUTICS, 2025, 24 (05) :678-691
[24]   Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma [J].
Liu, Hangqi ;
Zhang, Zhiwen ;
Chen, Longyun ;
Pang, Junyi ;
Wu, Huanwen ;
Liang, Zhiyong .
FRONTIERS IN ONCOLOGY, 2022, 11
[25]   PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair [J].
Luo, Qingying ;
Li, Yang ;
Deng, Jianjun ;
Zhang, Zunzhen .
CHEMICO-BIOLOGICAL INTERACTIONS, 2015, 226 :12-22
[26]   GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors [J].
Li, Yunzheng ;
Li, Binghua ;
Xu, Yanchao ;
Qian, Liyuan ;
Xu, Tiancheng ;
Meng, Gang ;
Li, Huan ;
Wang, Ye ;
Zhang, Laizhu ;
Jiang, Xiang ;
Liu, Qi ;
Xie, Yuanyuan ;
Cheng, Chunxiao ;
Sun, Beicheng ;
Yu, Decai .
CANCER RESEARCH, 2022, 82 (18) :3223-3235
[27]   Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors [J].
Funato, Kazuyoshi ;
Otsuka, Motoyuki ;
Sekiba, Kazuma ;
Miyakawa, Yu ;
Seimiya, Takahiro ;
Shibata, Chikako ;
Kishikawa, Takahiro ;
Fujishiro, Mitsuhiro .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 607 :89-95
[28]   Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells [J].
Gu, Wei Wei ;
Lin, Jie ;
Hong, Xing Yu .
ONCOTARGET, 2017, 8 (53) :90842-90851
[29]   mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer [J].
Mo, Wei ;
Liu, Qingxin ;
Lin, Curtis Chun-Jen ;
Dai, Hui ;
Peng, Yang ;
Liang, Yulong ;
Peng, Guang ;
Meric-Bernstam, Funda ;
Mills, Gordon B. ;
Li, Kaiyi ;
Lin, Shiaw-Yih .
CLINICAL CANCER RESEARCH, 2016, 22 (07) :1699-1712
[30]   Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature [J].
Batalini, Felipe ;
Madison, Russell W. ;
Sokol, Ethan S. ;
Jin, Dexter X. ;
Chen, Kuei-Ting ;
Decker, Brennan ;
Pavlick, Dean C. ;
Frampton, Garrett M. ;
Wulf, Gerburg M. ;
Garber, Judy E. ;
Oxnard, Geoffrey ;
Schrock, Alexa B. ;
Tung, Nadine M. .
JCO PRECISION ONCOLOGY, 2023, 7